Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : XENE save search
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
Published: 2023-11-27 (Crawled : 12:00) - globenewswire.com
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: 0.1%
H: 18.14%
C: 17.66%
xen1101 pharmaceuticals topline trial results
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: 0.31%
H: 3.31%
C: 3.06%
xen1101 publication pharmaceuticals trial results
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: -0.92%
H: 1.75%
C: -0.05%
xen1101 pharmaceuticals trial
Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
xen1101 treatment trial phase 2 major depressive disorder
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
Published: 2021-12-03 (Crawled : 12:30) - globenewswire.com
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: 1.77%
H: 0.0%
C: 0.0%
phase 2 phase 2b trial positive
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
Published: 2021-10-03 (Crawled : 00:00) - globenewswire.com
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: 69.5%
H: 22.03%
C: 18.82%
phase 2 results topline phase 2b trial conference
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021
Published: 2021-09-08 (Crawled : 14:00) - biospace.com/
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: 0.06%
H: 1.98%
C: -2.94%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: -0.62%
H: 1.8%
C: 1.72%
treatment phase 2 collaboration announces collaboration trial milestone
Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders
Published: 2021-07-07 (Crawled : 13:00) - globenewswire.com
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: -0.05%
H: 2.15%
C: 0.38%
phase 2 phase 2b trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.